# SRX Global Inc. (SRXH) — bankruptcy [announced]
Source: sec.gov · situation sit_b368decfc83b957ba684 · public 1621621423482753073 · retrieved 2026-09-03T13:28:35.518Z

## Overview
SRX Global Inc. (formerly SRx Health Solutions, Inc.) is a beverage company that has entered into a secured financing arrangement with CERo Therapeutics Holdings, Inc., a biopharmaceutical company developing T-cell therapies for cancer treatment.

SRX Global Inc. completed a secured financing transaction with CERo Therapeutics Holdings, Inc. on August 27, 2026, issuing a Consolidated Senior Secured Promissory Note that consolidates prior convertible grid promissory notes totaling $5,666,108.77 and provides for additional advances of up to $6,000,000, for a maximum aggregate loan amount of $11,666,108.77. The Company funded an initial advance of $775,665.00 on August 27, 2026, with CERO intending to use proceeds for outstanding trade payables and working capital. The Note bears interest at 10% per annum (24.99% upon Event of Default), matures on October 15, 2026 (extendable for up to four consecutive 30-day periods if no Event of Default occurs), and is secured by a first-priority security interest in all issued and outstanding capital stock of CERO's wholly owned subsidiary CERo Therapeutics, Inc., together with a security interest in substantially all of the subsidiary's assets including intellectual property, patents, patent applications, clinical trials, and regulatory applications relating to the CER-T cell therapy business, including CER-1236.

## Terms
- Counterparty: CERo Therapeutics Holdings, Inc. · Deal value: $11.7M · Consideration: cash

## Key dates
- Announced 2026-09-02 · Expiry 2026-10-15

## Timeline
- 2026-09-02 · 8-K (0001493152-26-041250): 8-K - SRX Global Inc. — *SRX Global Inc. (formerly SRx Health Solutions, Inc.) is a beverage company that has entered into a secured financing arrangement with CERo Therapeutics Holdings, Inc., a biopharmaceutical company developing T-cell therapies for cancer treatment.* SRX Global Inc. completed a secured financing transaction with CERo Therapeutics Holdings, Inc. on August 27, 2026, issuing a Consolidated Senior Secured Promissory Note that consolidates prior convertible grid promissory notes totaling $5,666,108.77 and provides for additional advances of up to $6,000,000, for a maximum aggregate loan amount of $11,666,108.77. The Company funded an initial advance of $775,665.00 on August 27, 2026, with CERO intending to use proceeds for outstanding trade payables and working capital. The Note bears interest at 10% per annum (24.99% upon Event of Default), matures on October 15, 2026 (extendable for up to four consecutive 30-day periods if no Event of Default occurs), and is secured by a first-priority security interest in all issued and outstanding capital stock of CERO's wholly owned subsidiary CERo Therapeutics, Inc., together with a security interest in substantially all of the subsidiary's assets including intellectual property, patents, patent applications, clinical trials, and regulatory applications relating to the CER-T cell therapy business, including CER-1236.
  https://www.sec.gov/Archives/edgar/data/1471727/0001493152-26-041250.txt

## Citations
- 0001493152-26-041250 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000149315226041250